

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

## **M.10955 - KIRK / LFI / ATP / FERROSAN MEDICAL DEVICES**

### **SECTION 1.2**

#### **Description of the concentration**

On 11 November 2022, the European Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 with regard to the acquisition of joint control over Ferrosan Medical Devices Group A/S between Kirk Kapital Strategic Investments A/S, Lundbeckfond Invest A/S, and Arbejdsmarkedets Tillægspension (jointly the “Parties”). The proposed concentration constitutes a concentration within the meaning of Article 3(1)(b) and 3(4) of Council Regulation 139/2004.<sup>16</sup>

The concentration will be completed following the acquisition of all the shares in Ferrosan Medical Devices Group A/S. Following the transaction, the Parties will exercise joint control over Ferrosan Medical Devices Group A/S.

Ferrosan Medical Devices Group A/S is a Danish limited liability company, which provide a range of innovative medical devices for healthcare professionals. The core of Ferrosan Medical Devices is the production of innovative biomaterial haemostatic medical devices to control critical bleeding in surgery. Ferrosan Medical Devices’ adjunctive haemostatic products consist of a flowable gelatin-based matrix as well as gelatinbased sponges and powder and are used exclusively in sterile environments, i.e., for surgical use only. Ferrosan Medical Devices’ primarily produces haemostatic products for human surgery, but also has one haemostatic product for veterinary surgery, i.e., for animal use only and, thus, accounting only for a minor part of the overall activities. Further, Ferrosan Medical Devices produces a breast biopsy system for performance of biopsies in relation to diagnosing breast cancer. The breast biopsy system is currently the only electromechanically device of Ferrosan Medical Devices portfolio and is also only used in sterile surroundings by healthcare professionals.

Kirk Kapital Strategic Investments A/S is a Danish limited liability company, which is 100 % owned by the Danish investment company Kirk Kapital A/S. Kirk Kapital A/S invests in Scandinavian medium-sized and larger-sized companies with a marketleading position in long-term growth industries.

Lundbeckfond Invest A/S is a Danish limited liability company, which is 100 % owned by Lundbeckfonden, a Danish commercial foundation. Lundbeckfond Invest A/S funds biomedical sciences research and is a long-term investor with controlling interests in the three Danish companies: H. Lundbeck A/S, a pharmaceutical company that specializes

---

<sup>16</sup>The Parties hereby consider the EU-Commission’s question #1 of **the RFI3** duly answered.  
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE  
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

in brain health, ALK-Abelló A/S, a pharmaceutical company that specializes in allergy immunotherapy, and Falck A/S, an international emergency response and healthcare service company. Further, Lundbeckfond Invest A/S is an investor in a portfolio of biotech companies, such as Dysis Medical Ltd.

Arbejdsmarkedets Tillægspension is a self-governing institution, established by the Danish Parliament by law. ATP manages the mandatory Danish pension scheme, ATP Livslang Pension, which is a collective pension scheme covering the majority of the Danish population. ATP invests the pension assets generated by ATP Livslang Pension by investing in a diverse portfolio of bonds, real estate and infrastructure in Denmark and abroad. ATP also manages the processing of welfare benefits on behalf of the Danish central government and Danish municipalities.